Blau Farmacêutica S.A. (BLAU3.SA)

BRL 12.57

(-5.42%)

EBITDA Summary of Blau Farmacêutica S.A.

Blau Farmacêutica S.A.'s latest annual EBITDA in 2023 was 410.54 Million BRL , down -53.18% from previous year.
Blau Farmacêutica S.A.'s latest quarterly EBITDA in 2024 Q2 was 89.5 Million BRL , up 8.33% from previous quarter.
Blau Farmacêutica S.A. reported an annual EBITDA of 527.03 Million BRL in 2022, up 4.64% from previous year.
Blau Farmacêutica S.A. reported an annual EBITDA of 533.3 Million BRL in 2021, up 33.08% from previous year.
Blau Farmacêutica S.A. reported a quarterly EBITDA of 53.84 Million BRL for 2024 Q1, up 11.51% from previous quarter.
Blau Farmacêutica S.A. reported a quarterly EBITDA of -60.16 Million BRL for 2023 Q3, down -156.53% from previous quarter.

Annual EBITDA Chart of Blau Farmacêutica S.A. (2023 - 2015)

Historical Annual EBITDA of Blau Farmacêutica S.A. (2023 - 2015)

Year	EBITDA	EBITDA Growth
2023	410.54 Million BRL	-53.18%
2022	527.03 Million BRL	4.64%
2021	533.3 Million BRL	33.08%
2020	388.7 Million BRL	23.41%
2019	312.5 Million BRL	51.76%
2018	206.75 Million BRL	20.81%
2017	170.41 Million BRL	98.43%
2016	76.14 Million BRL	36.62%
2015	53.37 Million BRL	0.0%

Year	EBITDA	EBITDA Growth
2024 Q2	89.5 Million BRL	8.33%
2024 Q1	53.84 Million BRL	11.51%
2023 Q3	-60.16 Million BRL	-156.53%
2023 Q1	71.62 Million BRL	-45.43%
2023 Q2	106.41 Million BRL	48.57%
2023 Q4	54.63 Million BRL	190.8%
2023 FY	- BRL	-53.18%
2022 FY	- BRL	4.64%
2022 Q4	131.26 Million BRL	-5.19%
2022 Q3	138.44 Million BRL	11.65%
2022 Q2	124 Million BRL	18.67%
2022 Q1	104.49 Million BRL	-2.21%
2021 Q4	106.85 Million BRL	-24.09%
2021 Q1	121.79 Million BRL	4.49%
2021 Q3	140.75 Million BRL	-8.17%
2021 Q2	153.28 Million BRL	25.85%
2021 FY	- BRL	33.08%
2020 Q2	115.85 Million BRL	155.21%
2020 FY	- BRL	23.41%
2020 Q4	116.56 Million BRL	2.12%
2020 Q3	114.13 Million BRL	-1.48%
2020 Q1	45.39 Million BRL	-46.76%
2019 Q3	89.42 Million BRL	-11.74%
2019 Q2	101.32 Million BRL	112.75%
2019 Q1	47.62 Million BRL	-31.42%
2019 FY	- BRL	51.76%
2019 Q4	85.27 Million BRL	-4.65%
2018 Q2	43.2 Million BRL	14.96%
2018 FY	- BRL	20.81%
2018 Q4	69.45 Million BRL	-5.72%
2018 Q3	73.66 Million BRL	70.5%
2018 Q1	37.58 Million BRL	0.0%
2017 FY	- BRL	98.43%
2016 FY	- BRL	36.62%
2015 FY	- BRL	0.0%

Peer EBITDA Comparison of Blau Farmacêutica S.A.

Name	EBITDA	EBITDA Difference
Hypera S.A.	2.9 Billion BRL	85.885%